Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Keros Therapeutics, Inc.

KROS · Nasdaq · CIK 0001664710 · Healthcare · Biotechnology

INSIDER SIGNAL

No active buy signal

4 qualifying P purchase groups
in the current 180-day scoring window

18 Form 4 transaction lines observed in the same window
8 sales · 6 option, withholding, award, gift or other lines

Last qualifying purchase2026-08-17 · BIENAIME JEAN JACQUES · $10.3K

WHY NO ACTIVE SIGNAL?

Purchase activityPresent
Recent buying4 qualifying line group(s)
Recent salesModerate
Buy signal statusInactive
Score anatomy

No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.

ClusterNot calculated
Purchase sizeNot calculated
RoleNot calculated
RecencyNot calculated
ConvictionNot calculated

Why is there no score?

  • No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
  • Sales and other Form 4 activity remain visible as context and do not create a negative score.

Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
BIENAIME JEAN JACQUESDirector
●○●●●
Newton Charles W.Director
▼▼
Farzan NimaDirector
○▼
Knowles JuliusDirector
○▼
Seth AlpnaDirector
○▼
GRAY MARY ANNDirector
○
● Purchase▼ Sale○ Other

Showing the six most active owners; 4 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: BIENAIME JEAN JACQUES · $41.6K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-05-15–2026-05-15

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

No recorded active-signal snapshot

Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2026-08-17 · BIENAIME JEAN JACQUES.

Recent Form 4 activity

6Purchases
12Sales
14Other Form 4 lines
29SEC filings · 365 days
BUYING4 qualifying P line(s) · 180 days
SELLING8 sale line(s) · context only
OTHER6 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,149,418
Previous report
1,342,620
Avg daily volume
205,020
Days to cover
5.6

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-17BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 10.27USD 10,270SEC filing ↗
2026-07-15BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 10.61USD 10,610SEC filing ↗
2026-06-15BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 10.19USD 10,190SEC filing ↗
2026-05-15BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 10.58USD 10,580SEC filing ↗
2026-04-15BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 11.70USD 11,700SEC filing ↗
2026-03-09BIENAIME JEAN JACQUESPurchase (P)Common Stock2,000USD 11.21USD 22,420SEC filing ↗
2025-04-09ADAR1 Capital Management GP, LLC; ADAR1 Capital Management, LLC; ADAR1 Partners, LP; Schneeberger DanielPurchase (P)Common Stock934,258USD 10.13USD 9,465,655SEC filing ↗
2020-11-17Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax Late Stage Fund L.P.; Pontifax Late Stage GP Ltd.; Pontifax Management 4 G.P. (2015) Ltd.Purchase (P)Common Stock60,000USD 50.00USD 3,000,000SEC filing ↗
2020-11-17Nussbaum Ran; Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax Late Stage Fund L.P.; Pontifax Late Stage GP Ltd.Purchase (P)Common Stock60,000USD 50.00USD 3,000,000SEC filing ↗
2020-11-17Kariv Tomer; Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax Late Stage Fund L.P.; Pontifax Late Stage GP Ltd.Purchase (P)Common Stock60,000USD 50.00USD 3,000,000SEC filing ↗
2020-04-13Knowles JuliusPurchase (P)Common Stock1,191USD 20.98USD 24,987SEC filing ↗
2020-04-13Seehra JasbirPurchase (P)Common Stock20,000USD 16.00USD 320,000SEC filing ↗
2020-04-13Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax Late Stage Fund L.P.; Pontifax Late Stage GP Ltd.; Pontifax Management 4 G.P. (2015) Ltd.Purchase (P)Common Stock437,499USD 16.00USD 6,999,984SEC filing ↗
2020-04-13ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock375,200USD 16.00USD 6,003,200SEC filing ↗
2020-04-13Nussbaum RanPurchase (P)Common Stock437,499USD 16.00USD 6,999,984SEC filing ↗

Form 4 evidence

32 transaction lines in the latest 365-day window; 521 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-18Tanini AnnitaSale (S)Common Stock1,224USD 10.29USD 12,595SEC filing ↗
2026-08-18Newton Charles W.Sale (S)Common Stock551USD 10.30USD 5,675SEC filing ↗
2026-08-18Lerner Lorena RaquelSale (S)Common Stock3,568USD 10.29USD 36,715SEC filing ↗
Show recent Form 4 evidence (29 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-18Tanini AnnitaSale (S)Common Stock1,224USD 10.29USD 12,595SEC filing ↗
2026-08-18Newton Charles W.Sale (S)Common Stock551USD 10.30USD 5,675SEC filing ↗
2026-08-18Lerner Lorena RaquelSale (S)Common Stock3,568USD 10.29USD 36,715SEC filing ↗
2026-08-18Cho EstherSale (S)Common Stock4,485USD 10.29USD 46,151SEC filing ↗
2026-08-17BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 10.27USD 10,270SEC filing ↗
2026-07-15BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 10.61USD 10,610SEC filing ↗
2026-07-01Prener AnneAward / grant (A)Common Stock13,786USD 0.00USD 0SEC filing ↗
2026-06-15BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 10.19USD 10,190SEC filing ↗
2026-06-11Newton Charles W.Sale (S)Common Stock550USD 10.04USD 5,522SEC filing ↗
2026-06-04Knowles JuliusSale (S)Common Stock2,625USD 10.73USD 28,166SEC filing ↗
2026-06-04Farzan NimaSale (S)Common Stock2,625USD 10.73USD 28,166SEC filing ↗
2026-06-04Seth AlpnaSale (S)Common Stock2,625USD 10.72USD 28,140SEC filing ↗
2026-06-03Seth AlpnaAward / grant (A)Common Stock7,142USD 0.00USD 0SEC filing ↗
2026-06-03Knowles JuliusAward / grant (A)Common Stock7,142USD 0.00USD 0SEC filing ↗
2026-06-03GRAY MARY ANNAward / grant (A)Common Stock7,142USD 0.00USD 0SEC filing ↗
2026-06-03Farzan NimaAward / grant (A)Common Stock7,142USD 0.00USD 0SEC filing ↗
2026-06-03BIENAIME JEAN JACQUESAward / grant (A)Common Stock7,142USD 0.00USD 0SEC filing ↗
2026-05-15BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 10.58USD 10,580SEC filing ↗
2026-04-15BIENAIME JEAN JACQUESPurchase (P)Common Stock1,000USD 11.70USD 11,700SEC filing ↗
2026-04-02Seehra JasbirOption exercise / conversion (M)Common Stock55,000USD 0.30USD 16,500SEC filing ↗
2026-03-09Newton Charles W.Award / grant (A)Common Stock13,215USD 0.00USD 0SEC filing ↗
2026-03-09BIENAIME JEAN JACQUESPurchase (P)Common Stock2,000USD 11.21USD 22,420SEC filing ↗
2026-02-19Seehra JasbirSale (S)Common Stock7,015USD 16.17USD 113,433SEC filing ↗
2026-02-18Regnante KeithSale (S)Common Stock4,739USD 16.35USD 77,483SEC filing ↗
2026-02-18Lerner Lorena RaquelSale (S)Common Stock3,873USD 16.35USD 63,324SEC filing ↗
2026-02-18Cho EstherSale (S)Common Stock4,745USD 16.35USD 77,581SEC filing ↗
2025-11-21ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCD (D)Common Stock214,522USD 17.75USD 3,807,766SEC filing ↗
2025-11-21Knowles JuliusD (D)Common Stock322,021USD 17.75USD 5,715,873SEC filing ↗
2025-11-21GORDON CARL LD (D)Common Stock214,522USD 17.75USD 3,807,766SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerKROS
CIK0001664710
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history521 transaction lines from 2020-04-13 to 2026-08-18
41 P purchase lines · 352 S sale lines · 128 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.